Onyx (, which develops cancer drugs and treatments, said Monday that Amgen's takeover bid of $120 a share undervalued the company. Onyx stock closed Friday at $86.82. )
"We are actively exploring the potential to combine Onyx with another company as an option to create additional value for Onyx shareholders," said Onyx CEO N. Anthony Coles.
Shares of Onyx rose more than 6% last week on news of Amgen's offer. Overall, the stock has increased nearly 36% since last year.
Amgen (Fortune 500) is a major player in biopharmaceuticals, and manufactures drugs for many conditions, including ones that counteract the effects of cancer treatments. ,
|Mark Zuckerberg calls Obama to complain about NSA|
|Number of millionaire households in the U.S. reaches high|
|Microsoft's next big headache: The Google Chromebook|
|Teens face toughest job market on record, study says|
|Microsoft launches cheaper Office 365 'Personal'|